Claims
- 1. A compound represented by generalized structure 1:
- 2. The compound of claim 1, wherein Z represents carboxylate.
- 3. The compound of claim 1, wherein G represents formyl.
- 4. The compound of claim 1, wherein X represents (CH(R))f.
- 5. The compound of claim 1, wherein R2 is absent.
- 6. The compound of claim 1, wherein f is 2.
- 7. The compound of claim 1, wherein Z represents carboxylate; and G represents formyl.
- 8. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; and X represents (CH(R))f.
- 9. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; and R2 is absent.
- 10. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; and f is 2.
- 11. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; X represents (CH(R))f; and R2 is absent.
- 12. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; X represents (CH(R))f; and f is 2.
- 13. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; R2 is absent; and f is 2.
- 14. The compound of claim 1, wherein Z represents carboxylate; G represents formyl; X represents (CH(R))f; R2 is absent; and f is 2.
- 15. A pharaceutical composition comprising a compound of any of claims 1-14 and a pharmaceutically acceptable carrier therefor.
- 16. A compound represented by generalized structure 2:
- 17. The compound of claim 16, wherein R3 is selected from the group consisting of:
- 18. The compound of claim 16, wherein J is selected from the group consisting
- 19. The compound of claim 17, wherein J is selected from the group consisting
- 20. The compound of claim 18, wherein Z represents carboxylate.
- 21. The compound of claim 18, wherein G represents formyl.
- 22. The compound of claim 18, wherein R represents independently for each occurrence hydrogen or methyl.
- 23. The compound of claim 18, wherein Z represents carboxylate; and G represents formyl.
- 24. The compound of claim 18, wherein Z represents carboxylate; G represents formyl; and R represents independently for each occurrence hydrogen or methyl.
- 25. A pharmaceutical composition comprising a compound of any of claims 16-24 and a pharmaceutically acceptable carrier therefor.
- 26. The compound of claim 1 or 16, wherein said compound has an IC50 less than 1 μM against an interleukin converting enzyme.
- 27. The compound of claim 1 or 16, wherein said compound has an IC50 less than 500 nM against an interleukin converting enzyme.
- 28. The compound of claim 1 or 16, wherein said compound has an IC50 less than 29. 250 nM against an interleukin converting enzyme.
- 29. A method of inhibiting an interleukin converting enzyme in a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or 16.
- 30. The method of claim 29, wherein said mammal is a primate, equine, canine or feline.
- 31. The method claim 29, wherein said mammal is a human.
- 32. The method of claim 29, wherein said compound or a pharmaceutical composition thereof is administered orally.
- 33. The method of claim 29, wherein said compound or a pharmaceutical composition thereof is administered intravenously.
- 34. The method of claim 29, wherein said compound or a pharmaceutical composition thereof is administered sublingually.
- 35. The method of claim 29, wherein said compound or a pharmaceutical composition thereof is administered ocularly.
- 36. A method of inhibiting interleukin-1β converting enzyme in a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or 16.
- 37. The method of claim 36, wherein said mammal is a primate, equine, canine or feline.
- 38. The method claim 36, wherein said mammal is a human.
- 39. The method of claim 36, wherein said compound or a pharmaceutical composition thereof is administered orally.
- 40. The method of claim 36, wherein said compound or a pharmaceutical composition thereof is administered intravenously.
- 41. The method of claim 36, wherein said compound or a pharmaceutical composition thereof is administered sublingually.
- 42. The method of claim 36, wherein said compound or a pharmaceutical composition thereof is administered ocularly.
- 43. A method of treating stroke, comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of claim 1 or 16.
- 44. A method of treating inflammatory diseases, comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of claim 1 or 16.
- 45. The method of claim 44, wherein said inflammatory disease is arthritis or inflammatory bowel disease.
- 46. A method of treating septic shock, comprising administering to a patient having septic shock a therapeutically effective amount of a compound of claim 1 or 16.
- 47. A method of treating reperfusion injury, comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of claim 1 or 16.
- 48. A method of treating Alzheimer's disease, comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of claim 1 or 16.
- 49. A method of treating shigellosis, comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of claim 1 or 16.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. 60/289,950 filed May 10, 2001 entitled “Arylsulfonamide Ethers, and Methods of Use Thereof”. The entire content of the foregoing provisional patent application is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60289950 |
May 2001 |
US |